In short
Clinical trials are investigating VX-993 in people with pain linked to diabetic peripheral neuropathy, a type of nerve pain caused by diabetes. The studies aim to evaluate whether VX-993 can reduce pain and how safe and tolerable it is. The current trial is in adults with this condition.
Key points
- Clinical trials are studying VX-993 in people with pain associated with diabetic peripheral neuropathy. The main trial is a Phase 2 interventional study with 300 participants. Researchers are checking whether VX-993 can reduce pain and whether it is safe and tolerable. The main endpoint is the change in weekly average daily pain intensity on the numeric pain rating scale at Week 12. The study is authorised and focuses on adults with this diabetes-related nerve pain.
Trial overview
The clinical trial for VX-993 is titled Evaluation of Efficacy and Safety of VX-993 for Pain Associated With Diabetic Peripheral Neuropathy.
This is an interventional study, which means researchers give study treatment and then measure the results.
The trial is in Phase 2 and is marked Authorised.
The planned enrollment is 300 people.
Who is being studied
This trial is studying people with pain associated with diabetic peripheral neuropathy.
Diabetic peripheral neuropathy is nerve damage caused by diabetes, and it can lead to pain in the feet, hands, or other areas.
The source data say the study is for subjects with this condition, but they do not give more detail about age limits or other eligibility rules.
What the study measures
The main goal is to see whether VX-993 can improve pain in people with diabetic peripheral neuropathy.
Researchers are also studying safety and tolerability, which means how well the treatment can be used and how well people can handle it.
The primary outcome is the change from baseline in the weekly average of daily pain intensity on the numeric pain rating scale (NPRS) at Week 12.
In simple terms, this means the study compares pain at the start with pain after 12 weeks to see if symptoms improve.
Study design and treatment groups
The intervention list shows VX-993 tablet and placebo groups, and it also lists pregabalin and pregabalin placebo.
A placebo is a look-alike treatment with no active study drug, used so researchers can compare results more fairly.
The trial data do not provide more detail about the exact group assignment method, but they do show that VX-993 is being compared with placebo and with pregabalin-related study groups.
What the results may mean
This trial is designed to answer a practical question: can VX-993 reduce pain in people living with diabetes-related nerve pain?
Because it is a Phase 2 study, the results may help show whether the treatment is promising enough for later research.
The study focuses on patient-reported pain scores, so the results depend on how participants rate their own pain over time.